|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Storage buffer||PBS with 4mg/ml BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, store in dark|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunocytochemistry (ICC)||See 1 publications below|
Commonly used, FITC conjugates provide relatively high absorptivity, excellent fluorescence quantum yield, and good water solubility.
CD22 (BL-CAM) is a type 1 integral membrane glycoprotein with molecular weight of 130 to 140 kD. It is expressed in both the cytoplasm and cell membrane of B-lymphocytes. CD22 antigen appears early in B-cell lymphocyte differentiation at approximately the same stage as the CD19 antigen. Unlike other B-cell markers, CD22 membrane expression is limited to the late differentiation stages comprised between mature B cells (CD22+) and plasma cells (CD22-), and may thus prove useful in phenotyping mature leukemias. CD22 is also strongly expressed in hairy cell leukemia.
Analyte Specific Reagent
Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.
MHCD2201 was used in immunocytochemistry to describe a phase I dose-escalation study where DT2219 is administered to patients with relapsed/refractory B-cell lymphoma or leukemia
|Bachanova V,Frankel AE,Cao Q,Lewis D,Grzywacz B,Verneris MR,Ustun C,Lazaryan A,McClune B,Warlick ED,Kantarjian H,Weisdorf DJ,Miller JS,Vallera DA||Clinical cancer research : an official journal of the American Association for Cancer Research (21:1267)||2015|